Compare · CV vs TMDX
CV vs TMDX
Side-by-side comparison of CapsoVision Inc. (CV) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CV and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.50B, about 7.7x CV ($324.3M).
- Over the past year, CV is up 51.8% and TMDX is down 31.3% - CV leads by 83.1 points.
- TMDX has been more active in the news (5 items in the past 4 weeks vs 3 for CV).
- TMDX has more recent analyst coverage (18 ratings vs 2 for CV).
- Company
- CapsoVision Inc.
- TransMedics Group Inc.
- Price
- $6.55-0.46%
- $72.31+1.53%
- Market cap
- $324.3M
- $2.50B
- 1M return
- -7.88%
- -6.89%
- 1Y return
- +51.80%
- -31.29%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2019
- News (4w)
- 3
- 5
- Recent ratings
- 2
- 18
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest CV
- Large owner Harari Eliyahou Et Al bought $410,988 worth of shares (61,068 units at $6.73) (SEC Form 4)
- Large owner Harari Eliyahou Et Al bought $495,117 worth of shares (81,300 units at $6.09) (SEC Form 4)
- Large owner Harari Eliyahou Et Al bought $101,811 worth of shares (13,850 units at $7.35) (SEC Form 4)
- SEC Form 4 filed by Director Shields David Stanley
- New insider Shields David Stanley claimed no ownership of stock in the company (SEC Form 3)
- CapsoVision Inc. filed SEC Form 8-K: Regulation FD Disclosure
- CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D., to Board of Directors
- Director Imperial Joanne Carol exercised 2,022 shares at a strike of $7.58, increasing direct ownership by 120% to 3,709 units (SEC Form 4)
- Amendment: Director Imperial Joanne Carol sold $8,587 worth of shares (1,200 units at $7.16), decreasing direct ownership by 42% to 1,687 units (SEC Form 4)
- Director Tsai Chen Lung exercised 2,022 shares at a strike of $7.58, increasing direct ownership by 70% to 4,929 units (SEC Form 4)
Latest TMDX
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)
- President & CEO Hassanein Waleed H was granted 49,669 shares, increasing direct ownership by 41% to 171,093 units (SEC Form 4)
- TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
- Director Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)
- Director Gunderson Thomas J. was granted 2,922 shares, increasing direct ownership by 72% to 6,981 units (SEC Form 4)